About Nanopath
Nanopath makes rapid infection tests for clinicians caring for women with pelvic or urinary symptoms. Its single-use cartridge and benchtop reader look for genetic traces from disease-causing microbes at the point of care. The system can identify several urinary-tract pathogens and antibiotic-resistance markers from one urine sample in about 15 minutes.
Nanopath is based at The Engine built by MIT in Cambridge. Co-founders Amogha Tadimety and Alison Burklund serve as co-chief executives. Its team spans nanotechnology, assay development, and engineering.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | Nov 13, 2026 | $29,891,706of $36.7M target | 21 | $1.4M | Equity, DebtRule 506(b) | Form D ↗ |
| Jan 24, 2025 | Feb 6, 2025 | $5,341,000of $6.0M target | 5 | $1.0M | DebtRule 506(b) | Form D ↗ |
| Jun 14, 2022 | Aug 9, 2022 | $10,000,000fully sold | 10 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $45,232,706 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
What the SEC Filings Show
- Aaron Sandoski of Medtech Convergence Fund, which co-led the Series A round, first appears as a director on the Form D that Nanopath filed on February 6, 2025. [11][14][4]Form D filings that name Aaron Sandoski (21):
- Daktari Diagnostics, director: Aug 26, 2009 · Jul 2, 2010 · Nov 3, 2010 · Aug 16, 2011 · Dec 27, 2011 · May 13, 2013 · Apr 7, 2014 (amended) · Mar 13, 2015 · May 25, 2016 (amended)
- Podimetrics, director: Oct 11, 2012 · Mar 27, 2013 (amended) · Oct 29, 2014 · Jan 19, 2016 · May 27, 2016 (amended) · Oct 25, 2017 · Apr 6, 2022
- Alpheus Medical, director: Dec 23, 2020 · Nov 9, 2022
- Nanopath, board Director: Feb 6, 2025 · Nov 13, 2026
- Lexington Medical, director: Apr 29, 2025
- Series A began taking money on June 14, 2022, 56 days before the announcement. The Form D filed on August 9, 2022 shows $10.0 million sold, the full offering, from 10 investors, or about $1.0 million each. [12]
- Jeff Crowe of Norwest Venture Partners, which co-led the Series A round, first appears as a director on the Form D that Nanopath filed on August 9, 2022. [12][15][4]Form D filings that name Jeff Crowe (50):
- LendingClub, director: Mar 27, 2009 · May 4, 2010 · Aug 19, 2011
- RetailMeNot, director: Dec 3, 2010 · Jun 3, 2011 · Aug 22, 2011 · Nov 14, 2011 · Apr 9, 2013 (amended)
- Turn, director: Jan 26, 2011 · Mar 14, 2013 · Jan 14, 2014 · Jan 14, 2014 · Mar 16, 2016
- Madison Reed, senior Managing Partner, Norwest Venture Partners and director: Apr 17, 2014 · Sep 25, 2015 · Jul 28, 2016 · Oct 20, 2017 · Oct 30, 2017 (amended) · Feb 5, 2019 · Apr 15, 2020 · Jun 30, 2020 · Sep 22, 2021 · Mar 13, 2026
- Extole, director: Dec 8, 2014 · Apr 5, 2017 · Jan 29, 2020 (amended) · Jan 25, 2023 (amended)
- Glint, director: Apr 27, 2015 · Apr 27, 2015 · Aug 30, 2016 · Nov 14, 2016 · Nov 3, 2017 · Nov 3, 2017 (amended)
- Grove Collaborative, director: Jan 18, 2018 · Dec 26, 2018 · Dec 27, 2018 · Sep 9, 2019 · May 15, 2020 · Dec 10, 2020
- Button, director: Jul 1, 2019 · Jul 1, 2019
- ICON, director: Aug 25, 2021 · Feb 18, 2022 · Feb 13, 2025 · Aug 26, 2026
- Praxis Labs, director: Nov 1, 2021
- Nanopath, board Director: Aug 9, 2022 · Feb 6, 2025 · Nov 13, 2026
- Minted, director: May 23, 2025
Who Invested in Nanopath
Scroll table to see all columns →
| Announced | Round | Amount | Lead | Other investors | On the Form D | Source |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Series B | $25 million | — | — | [13] | |
| Aug 9, 2022 | Series A | $10 million | Norwest Venture Partners; Medtech Convergence Fund | Gingerbread Capital and Green D Ventures | First sale Jun 14, 2022; $10,000,000 of $10,000,000 from 10 investors. [12] | [4] |
Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
Why Investors Backed Nanopath
Standard tests can take days, delaying targeted treatment and adding to antibiotic resistance. Norwest backed Nanopath because its platform could offer comparable or better accuracy in 15 minutes and at lower cost. [8][4]
“Nanopath has hit on a new approach that is poised to disrupt the existing molecular testing paradigm.”
Origin and Team
Nanopath spun out of Dartmouth College in 2019 with Dartmouth Hitchcock Medical Center. Amogha Tadimety and Alison Burklund are its co-founders. [4][2]
Product and Technology
The platform uses ultrasensitive optical detection to find DNA and RNA without amplifying the sample. Removing amplification reduces reagents, cost, and operator steps. [4]
For complicated urinary infections, the cartridge-reader system is designed to identify pathogens and antibiotic-resistance markers from urine in about 15 minutes. [7]
The development plan calls for a panel covering more than 95% of UTI-causing organisms and a pilot study with over 200 patients at Brigham & Women’s Hospital. [8]
By October 2025, Nanopath had improved platform sensitivity more than 1,000-fold and shortened the time needed for results. [6]
Use of Funds
- The Series A was intended to expand the technical team and begin commercial and clinical partnerships. [4]
- The Series A also supported development and commercialization of the biosensing platform for pelvic and gynecologic infections. [4]
- The federal grants funded the test consumable, readout instrument, and analytical and clinical validation of the lead assay. [5]
Milestones
Scroll table to see all columns →
| Date | What happened | Source | Coverage |
|---|---|---|---|
| Nov 18, 2025 | The FDA granted Breakthrough Device designation to Nanopath’s assay for suspected or high-risk complicated urinary tract infections. | [7] | — |
| Oct 16, 2025 | Nanopath added five experts to its leadership and executive team. | [6] | — |
| May 21, 2024 | NIH awarded Nanopath a $3 million Small Business Innovation Research grant for its pelvic and gynecologic infection platform. | [5] | — |
| May 21, 2024 | NSF awarded Nanopath a $1 million Small Business Innovation Research grant for the same platform. | [5] | — |
| May 21, 2024 | Nanopath had developed advanced prototypes of its disposable cartridge and benchtop reader. | [5] | — |
| Jul 2022 | Nanopath won the AACC Disruptive Technology Award. | [4] | Association for Diagnostics & Laboratory Medicine ↗ |
| Dec 2021 | Nanopath won the inaugural Ignite Golden Ticket. | [3] | — |
Market
Norwest’s Jeff Crowe viewed women’s-health diagnostics as ready for more actionable results that fit current and emerging care models. [4]
Nanopath argues that women’s health remains underfunded and under-researched. [5]
We wrote this summary from public statements by Nanopath and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Nanopath's Form D filed Nov 13, 2026.
Sources
- CompanyNanopath homepage · linked above ↑
- CompanyNanopath team and careers
- CompanyNanopath news and resources
- PressNanopath $10 million Series A announcement
- PressNanopath federal grants announcement
- PressNanopath leadership expansion announcement
- PressNanopath FDA designation announcement
- ResearchSBIR Nanopath project summary
- PressADLM profile of Nanopath’s biosensing platform · linked above ↑
- SECNanopath Form D, filed 2026-11-13 · linked above ↑
- SECNanopath Form D, filed 2025-02-06 · linked above ↑
- SECNanopath Form D, filed 2022-08-09 · linked above ↑
- AnnouncementCompany release
- ProfileAaron Sandoski at Medtech Convergence Fund · linked above ↑
- ProfileJeff Crowe at Norwest Venture Partners · linked above ↑
- SECNanopath Inc filing history